Update on the treatment of overactive bladder

Current Opinion in Urology

Volumn 21, Issue 4, 2011, Pages 286-290

  Dmochowski, Roger R ^a,b   Gomelsky, Alex ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

neuromodulation; overactive bladder; treatment; urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; DARIFENACIN; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TAMSULOSIN; TOLTERODINE; TROSPIUM CHLORIDE;

ADD ON THERAPY; ARTICLE; CHRONIC PAIN; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; INTERMITTENT CATHETERIZATION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MICTURITION; MULTICENTER STUDY (TOPIC); NERVE STIMULATION; OVERACTIVE BLADDER; PATIENT SATISFACTION; PERCUTANEOUS TIBIAL NERVE STIMULATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SACRAL NERVE STIMULATION; TIBIAL NERVE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA;

BOTULINUM TOXINS, TYPE A; ELECTRIC STIMULATION THERAPY; HUMANS; LUMBOSACRAL PLEXUS; MUSCARINIC ANTAGONISTS; PATIENT SELECTION; TIBIAL NERVE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 79959222278     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3283468da3     Document Type: Article

References (27)

1. Abrams P, Andersson KE, Birder L, et al., Members of Committees; Fourth International Consultation on Incontinence. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010; 29: 213-240.
2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20:327-336 (Pubitemid 44175300)
3. Koyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well being in men and women: results from the EPIC study. BJU Int 2008; 101:1388-1395 (Pubitemid 351623990)
4. Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care 2009; 15:S98-S107
5. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004; 63:461-465
6. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54:543-562
7. Herschorn S, Pommerville P, Stothers L, et al. Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (-65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. J Curr Med Res Opin 2011; 27:375-382
8. Masumori N, Tsukamoto T, YanaseM, et al. The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction. Adv Urol 2010:205251
9. Bolduc S, Moore K, Nadeau G, et al. Prospective open label study of solifenacin for overactive bladder in children. J Urol 2010; 184:1668-1673
10. Chapple C. New once-daily formulation for trospium in overactive bladder. Int J Clin Pract 2010; 64:1535-1540
11. Staskin DR, Rosenberg MT, Sand PK, et al. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract 2009; 63:1715-1723
12. Bödeker RH, Madersbacher H, Neumeister C, Zellner M. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol 2010; 10: 15.
13. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52:1204-1212 (Pubitemid 47332062)
14. Goldman HB, Morrow JD, Gong J, et al. Early onset of fesoterodine efficacy in subjects with overactive bladder. BJU Int 2011; 107:598-602
15. Dmochowski RR, Peters KM, Morrow JD, et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology 2010; 75:62-68
16. Wyndaele JJ, Goldfischer ER, Morrow JD, et al. Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. BJU Int 2011; 107:603-611
17. Kaplan SA, Schneider T, Foote JE, et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int 2010 [Epub ahead of print]. doi: 10.1111/j.1464-410x.2010.09640.x
18. Starkman JS, Smith CP, Staskin DR. Surgical options for drug-refractory overactive bladder patients. Rev Urol 2010; 12:e97-e110
19. Marcelissen TAT, Leong RK, de Bie RA, et al. Long-term results of sacral neuromodulation with the tined lead procedure. J Urol 2010; 184:1997- 2000
20. Leong RK, Marcelissen TA, Nieman FH, et al. Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey. J Urol 2011; 185:588-592
21. Stoller ML. Afferent nerve stimulation for pelvic floor dysfunction. Eur Urol 1999; 35:132
22. Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the Overactive Bladder Innovative Therapy trial. J Urol 1055; 182:
23. MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol 2010; 183:234-240
24. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010; 183:1438
25. Finazzi-Agro E, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol 2010; 184:2001- 2006
26. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxin A for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010; 18:2416-2422
27. Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin A injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 2010; 58:919-926